Effect of oral bismuth subsalicylate on campylobacter pylori and on healing and relapse rate of peptic ulcer

Reviews of Infectious Diseases

Volumn 12, Issue , 1990, Pages S115-S119

  Eberhardt, Reinhild ^a   Kasper, Gerhard ^a  

^a KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE; CIMETIDINE;

ADULT; AGED; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HELICOBACTER PYLORI; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; STOMACH ANTRUM; TONGUE DISEASE; TOOTH COLOR; ULCER HEALING;

ADULT; AGED; BIOPSY; BISMUTH; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CIMETIDINE; FEMALE; FOLLOW-UP STUDIES; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SALICYLATES;

EID: 0025162049     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/12.Supplement_1.S115     Document Type: Article

References (21)

1. Lee F.I., Samloff I.M., Hardman M. Comparison of tripotassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1:1299–302
2. Bianchi Porro G., Lazzaroni M., Petrillo M., De Nicola C. Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine [letter]. Lancet 1984;2:698
3. Bianchi Porro G., Barbara L., Cheli R., Dal Monte P.R., Mazzacca G. Comparison of tripotassium dicitrato bismuthate (TDB) tablets and ranitidine in healing and relapse of duodenal ulcers [abstract no. F51]. Gut 1984;25:A565
4. Sutton D.R. Gastric ulcer healing with tripotassium dicitrate bismuthate and subsequent relapse. Gut 1982;23:621–4
5. Marshall B.J., McGechie D.B., Rogers P.A., Glancy R.J. Pyloric campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439–44
6. Goodwin C.S., Armstrong J.A., Marshall B.J. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986;39:353–65
7. Marshall B.J., Armstrong J.A., McGechie D.B., Glancy R.J. Attempt to fulfill Koch’s postulates for pyloric Campylobacter. Med J Aust 1985;142:436–9
8. Pyloric Campylobacter finds a volunteer [editorial]. Lancet 1985;1:1021–2
9. Morris A., Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987;82:192–9
10. Kasper G., Dickgieber N. Klinische Bedeutung, Epidemiologie and Laboratoriumsdiagnostik von Campylobacter pyloridis. Immun Infekt 1986;14:58–62
11. Vantrappen G., Schuurmans P., Rutgeerts P., Janssens J. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer. Scand J Gastroenterol [Suppl] 1982;80:23–30
12. Goodwin C.S., Armstrong J.A. Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer? J An- timicrob Chemother 1986;17:1–3
13. Jones D.M., Lessells A.M., Eldridge J. Campylobacter-like organisms on the gastric mucosa: culture, histological, and serological studies. J Clin Pathol 1984;37:1002–6
14. Langenberg M.L., Tytgat G.N.J., Schipper M.E.I., Rietra P.J.G., Zanen H.C. Campylobacter-like organisms in the stomach of patients and healthy individuals [letter]. Lancet 1984; 1:1348
15. Rauws E.A.J., Langenberg W., Houthoff H.J., Zanen H.C., Tytgat G.N. Campylobacter pyloridis-associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988;94:33–40
16. Martin D.F., May S.F., TWeedle D.E.F., Hollanders D., Ravenscroft M.M., Miller J.P. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981;1:7–10
17. McNulty C.A.M., Gearty J.C., Crump B., Davis M., Donovan I.A., Melikian V., Lister D.M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 1986;293:645–9
18. Goodwin C.S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Che- mother 1986;17:309–14
19. McNulty C.A.M., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. J Antimicrob Chemother 1985;28:837–8
20. Hamilton I., O’Connor H.J., Wood N.C., Bradbury I., Axon A.T.R. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrate bismuthate (TBE) tablets or cimetidine. Gut 1986;27:106–10
21. McLean A.J., Harrison P.M., Ioannides-Demos L.L., Byrne A.J., McCarthy P., Dudley F.J. Microbes, peptic ulcer, and relapse rates with different drugs. Lancet 1984;2:525–6